{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.2","upperLimit":"87.3","value":"76.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Biochemical progression free survival is defined as the time from enrollment in the study until development of overt clinical multiple myeloma (end organ damage or myeloma-defining event) or death, and progressive disease by International Myeloma Working Group (IMWG) criteria. Progression is any one of the following: Increase of ≥25% from lowest response value in the following on 2 consecutive measurements: Serum M-component and/or (the absolute increase must be ≥0.5g/dl). The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥0.5g/dl. Urine M-component and/or (the absolute must be ≥200mg/24h. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels. The absolute increase must be \\>10mg/dl. Bone marrow plasma cell percentage: the absolute % must be ≥10%.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib (intravenous (IV), Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (by mouth (PO), Days 1-21 of the 28-day cycle; exception: not given on cycle 1 day 1); and Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1)\n\nCarfilzomib intravenous (IV) 20-36 mg/m\\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.\n\nRevlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"54/55 participants are evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"time from enrollment in the study until development of overt clinical multiple myeloma (end organ damage or myeloma-defining event) or death, and progressive disease by IMWG criteria, up to 5 years","title":"Biochemical Progression Free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}